Middle-molecule clearance at 20 and 35 ml/kg/h in continuous venovenous hemodiafiltration

Area of Science:

• Nephrology
• Critical Care Medicine
• Biomedical Engineering

Background:

• Clinical trials on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) have yielded conflicting results regarding dose-response benefits.
• Blood-membrane interactions in continuous venovenous hemodiafiltration may limit the impact of CRRT dose adjustments on macromolecule transport.
• Previous studies suggest that CRRT dosing arms in the Acute Renal Failure Trial Network (ATN) study might have provided similar middle-molecule clearances.

Purpose of the Study:

• To investigate the impact of CRRT dosing on middle-molecule clearance using a simulation model.
• To determine if CRRT dose separation in the ATN study affected small versus middle-molecule clearance.
• To reconcile differing outcomes in previous CRRT clinical trials.

Main Methods:

• Simulated two CRRT doses from the ATN study using bovine blood and a synthetic polydisperse macromolecular probe.
• Measured the clearance of tracers ranging from 10 to 100 kDa molecular weight over a 6-hour period.
• Utilized a simulation approach to control variables and assess specific clearance parameters.

Main Results:

• A minimal difference in middle-molecule clearance, less than 2 ml/min, was observed between the two simulated CRRT dosing arms.
• The CRRT prescription in the ATN study demonstrated effective dose separation for small molecules.
• Middle-molecule clearance remained largely consistent across the tested CRRT doses.

Conclusions:

• The CRRT dosing strategy in the ATN study achieved dose separation for small molecules but not for middle molecules.
• This lack of middle-molecule clearance variability may explain discrepancies between the ATN study and prior CRRT trials.
• Findings suggest a need for revised trial designs in future CRRT research to better differentiate dose effects.